Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBDEX 10 spray in adults with type 2 diabetes
IRCT20121021011192N10Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cannabidiol in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Change in hemoglobin A1C serum level. Started Jan 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20121021011192N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20121021011192N10.